Expression of SOCS3 and HER2 in breast cancer and their clinicopathological significance
10.3760/cma.j.cn431274-20240710-01061
- VernacularTitle:乳腺癌中SOCS3与HER2的表达及其临床病理意义
- Author:
Bo HUANG
1
;
Zihui HUANG
1
;
Chunyao LI
1
Author Information
1. 南方医科大学第十附属医院(东莞市人民医院)病理科，东莞市临床病理重点实验室，东莞 523000
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Suppressor of cytokine signaling-3;
Human epidermal growth factor receptor 2
- From:
Journal of Chinese Physician
2024;26(12):1851-1856
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of suppressor of cytokine signaling-3 (SOCS-3) and human epidermal growth factor receptor 2 (HER2) protein and gene in breast cancer and their clinicopathological significance.Methods:A total of 900 female cases of breast invasive ductal carcinoma admitted to the Tenth Affiliated Hospital of Southern Medical University from July 2019 to June 2024 were selected for surgical resection, and none of them had received chemotherapy or radiotherapy before surgery. SOCS3 and HER2 antibody immunohistochemical staining were performed on the normal breast tissues with adjacent cancer as control, and the results were interpreted. Cases with uncertain expression level of HER2 protein (2+ ) were confirmed by fluorescence in situ hybridization (FISH). The differences of SOCS3 and HER2 expression in breast cancer tissues with different Nottingham histological grade, with or without lymph node metastasis, and with different number of lymph node metastasis were analyzed.Results:Immunohistochemical results showed that the positive expression rate of SOCS3 in breast cancer tissues was lower than that in adjacent normal tissues [5.4%(49/900) vs 56.8%(511/900)], and the difference was statistically significant ( P<0.05). In breast cancer tissues, HER2 expression was 2+ in 212 cases, 3+ in 111 cases, and HER2 expression was 2+ in 91 cases and 3+ in 0 cases in adjacent normal tissues. Two groups of patients with 2+ expression were tested by FISH. The results showed that 90 patients were positive for breast cancer and 122 were negative. There were 16 positive and 75 negative adjacent normal tissues. Immunohistochemistry and FISH results confirmed that the positive expression rate of HER2 in breast cancer tissues was higher than that in adjacent normal tissues [22.3%(201/900) vs 1.8%(16/900)], and the difference was statistically significant ( P<0.05). The higher the Nottingham histological grade, the breast cancer with lymph node metastasis and multiple lymph node metastasis, the higher the HER2 positive expression rate (all P<0.05), and the lower the SOCS3 positive expression rate (all P<0.05). Conclusions:The difference in the expression of HER2 and SOCS3 in breast cancer is related to the Nottingham histological grade, the presence or absence of lymph node metastasis, and the number of lymph node metastasis. The high expression of HER2 and low expression of SOCS3 suggest poor prognosis of breast cancer patients.
